hVIVO plc Stock

Equities

HVO

GB00B6ZM0X53

Healthcare Facilities & Services

Delayed London S.E. 5-day change 1st Jan Change
- GBX -.--% Intraday chart for hVIVO plc +18.92% +41.94%
Sales 2017 10.88M 13.53M Sales 2018 11.02M 13.72M Capitalization 22.57M 28.08M
Net income 2017 -12M -14.93M Net income 2018 -16M -19.91M EV / Sales 2017 2.09 x
Net cash position 2017 20.29M 25.24M Net cash position 2018 13.37M 16.63M EV / Sales 2018 0.83 x
P/E ratio 2017
-3.33 x
P/E ratio 2018
-1.31 x
Employees -
Yield 2017 *
-
Yield 2018
-
Free-Float 91.04%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer 55 -
Director of Finance/CFO 61 -
Chief Tech/Sci/R&D Officer - 22-06-30
Members of the board TitleAgeSince
Director/Board Member 57 22-05-31
Chairman 59 20-03-31
Director/Board Member 73 -
More insiders
hVIVO plc, formerly Retroscreen Virology Group plc, is a holding company. The Company is engaged in a life sciences business pioneering a technology platform of human disease models to accelerate drug discovery and development in respiratory and infectious diseases, including flu, respiratory syncytial virus (RSV), asthma and common cold. It has commercialized approximately four disease models, enrolled over 2,000 subjects and conducted approximately 40 product validation studies for a range of industry, government and academic clients and collaborators. The Company offers services, such as challenge study services, lab services, and target and biomarker discovery. It offers viral challenge studies in healthy volunteers in influenza, human rhinovirus (HRV) and RSV. Its lab services include assay development, transfer and optimization across the immunological, molecular and cell-based assay platforms, including offering options in sample matrix testing and specialty biomarker assays.
More about the company